Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1982 1
1983 1
1984 2
1985 3
1987 1
1988 1
1989 2
1990 2
1991 5
1992 4
1993 5
1994 10
1995 7
1996 5
1997 3
1998 9
1999 10
2000 10
2001 6
2002 8
2003 9
2004 11
2005 8
2006 11
2007 13
2008 13
2009 7
2010 12
2011 9
2012 16
2013 9
2014 15
2015 14
2016 20
2017 14
2018 19
2019 25
2020 23
2021 25
2022 18
2023 8
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

369 results

Results by year

Filters applied: . Clear all
Page 1
Preface.
Bunt C, Urtti A, Thrimawithana T. Bunt C, et al. Among authors: urtti a. Adv Drug Deliv Rev. 2018 Feb 15;126:1-2. doi: 10.1016/j.addr.2018.05.003. Adv Drug Deliv Rev. 2018. PMID: 29887021 No abstract available.
Polysaccharides in Ocular Drug Delivery.
Dubashynskaya N, Poshina D, Raik S, Urtti A, Skorik YA. Dubashynskaya N, et al. Among authors: urtti a. Pharmaceutics. 2019 Dec 24;12(1):22. doi: 10.3390/pharmaceutics12010022. Pharmaceutics. 2019. PMID: 31878298 Free PMC article. Review.
Mass spectrometry in ocular drug research.
Del Amo EM, Vellonen KS, Urtti A, Terasaki T, Hammid A, Honkakoski P, Auriola S. Del Amo EM, et al. Among authors: urtti a. Mass Spectrom Rev. 2023 Aug 2. doi: 10.1002/mas.21861. Online ahead of print. Mass Spectrom Rev. 2023. PMID: 37530668 Review.
Oligonucleotide theme.
Urtti A. Urtti A. Eur J Pharm Sci. 2000 May;10(3):167. doi: 10.1016/s0928-0987(00)00066-x. Eur J Pharm Sci. 2000. PMID: 10767593 No abstract available.
Pharmacokinetic aspects of retinal drug delivery.
Del Amo EM, Rimpelä AK, Heikkinen E, Kari OK, Ramsay E, Lajunen T, Schmitt M, Pelkonen L, Bhattacharya M, Richardson D, Subrizi A, Turunen T, Reinisalo M, Itkonen J, Toropainen E, Casteleijn M, Kidron H, Antopolsky M, Vellonen KS, Ruponen M, Urtti A. Del Amo EM, et al. Among authors: urtti a. Prog Retin Eye Res. 2017 Mar;57:134-185. doi: 10.1016/j.preteyeres.2016.12.001. Epub 2016 Dec 24. Prog Retin Eye Res. 2017. PMID: 28028001 Free article. Review.
Mathematical Models of Ocular Drug Delivery.
Sadeghi A, Subrizi A, Del Amo EM, Urtti A. Sadeghi A, et al. Among authors: urtti a. Invest Ophthalmol Vis Sci. 2024 Sep 3;65(11):28. doi: 10.1167/iovs.65.11.28. Invest Ophthalmol Vis Sci. 2024. PMID: 39287588 Free PMC article. Review.
Modified cells as potential ocular drug delivery systems.
Tennikova T, Urtti A. Tennikova T, et al. Among authors: urtti a. Drug Discov Today. 2019 Aug;24(8):1621-1626. doi: 10.1016/j.drudis.2018.12.004. Epub 2018 Dec 15. Drug Discov Today. 2019. PMID: 30562585 Review.
Formulation and stability of cytokine therapeutics.
Lipiäinen T, Peltoniemi M, Sarkhel S, Yrjönen T, Vuorela H, Urtti A, Juppo A. Lipiäinen T, et al. Among authors: urtti a. J Pharm Sci. 2015 Feb;104(2):307-26. doi: 10.1002/jps.24243. Epub 2014 Dec 9. J Pharm Sci. 2015. PMID: 25492409 Review.
Expression, activity and pharmacokinetic impact of ocular transporters.
Vellonen KS, Hellinen L, Mannermaa E, Ruponen M, Urtti A, Kidron H. Vellonen KS, et al. Among authors: urtti a. Adv Drug Deliv Rev. 2018 Feb 15;126:3-22. doi: 10.1016/j.addr.2017.12.009. Epub 2017 Dec 14. Adv Drug Deliv Rev. 2018. PMID: 29248478 Review.
369 results